CTLA-4 Antibody (F-8): sc-376016

CTLA-4 Antibody (F-8) is a mouse monoclonal IgG1 kappa light chain antibody specifically engineered to target cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), also known as CD152, by recognizing an epitope within amino acids 195-223 at the C-terminus of the human protein. CTLA-4 is a crucial immune checkpoint receptor predominantly located on the surface of activated T cells, where CTLA-4 plays a vital role in downregulating immune responses by competing with the stimulatory receptor CD28 for binding to B7 ligands (CD80/CD86) on antigen-presenting cells. This strategic cellular localization is essential for maintaining immune homeostasis and preventing excessive immune activation that could lead to autoimmunity, making anti-CTLA-4 antibody (F-8) a key target for immunological research and therapeutic interventions. CTLA-4 monoclonal antibody (F-8) demonstrates broad species reactivity, effectively detecting CTLA-4 from mouse, rat, and human origins in various applications including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), and enzyme-linked immunosorbent assay (ELISA), as well as cross-reacting with CTLA-4 from equine, canine, bovine, and porcine species. CTLA-4 (F-8) antibody serves as an invaluable tool for investigating the inhibitory pathways that modulate T cell activation and proliferation, thereby advancing research in immunology, cancer immunotherapy, and autoimmune disease models. Available in both non-conjugated and various conjugated forms, including horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® variants, CTLA-4 (F-8) monoclonal antibody offers versatility and robustness for diverse experimental needs.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

CTLA-4 Antibody (F-8) References:

1. Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy.  |  Schwartz, RH. 1992. Cell. 71: 1065-8. PMID: 1335362
2. Structure, expression, and T cell costimulatory activity of the murine homologue of the human B lymphocyte activation antigen B7.  |  Freeman, GJ., et al. 1991. J Exp Med. 174: 625-31. PMID: 1714935
3. Regulation of CD28 expression on CD8+ T cells by CTLA-4.  |  Berg, M. and Zavazava, N. 2008. J Leukoc Biol. 83: 853-63. PMID: 18162511
4. Genetic basis for clinical response to CTLA-4 blockade in melanoma.  |  Snyder, A., et al. 2014. N Engl J Med. 371: 2189-2199. PMID: 25409260
5. Immune deficiency and autoimmunity in patients with CTLA-4 (CD152) mutations.  |  Verma, N., et al. 2017. Clin Exp Immunol. 190: 1-7. PMID: 28600865
6. CTLA-4 tail fusion enhances CAR-T antitumor immunity.  |  Zhou, X., et al. 2023. Nat Immunol. 24: 1499-1510. PMID: 37500885
7. CTLA-4-expressing ILC3s restrain interleukin-23-mediated inflammation.  |  Ahmed, A., et al. 2024. Nature. 630: 976-983. PMID: 38867048
8. Potential roles of the B7 and CD28 receptor families in autoimmunity and immune evasion.  |  Harlan, DM., et al. 1995. Clin Immunol Immunopathol. 75: 99-111. PMID: 7535672
9. Identification of residues in the V domain of CD80 (B7-1) implicated in functional interactions with CD28 and CTLA4.  |  Fargeas, CA., et al. 1995. J Exp Med. 182: 667-75. PMID: 7544393
10. Both extracellular immunoglobin-like domains of CD80 contain residues critical for binding T cell surface receptors CTLA-4 and CD28.  |  Peach, RJ., et al. 1995. J Biol Chem. 270: 21181-7. PMID: 7545666
11. A novel receptor involved in T-cell activation.  |  Cocks, BG., et al. 1995. Nature. 376: 260-3. PMID: 7617038
12. CTLA4 mediates antigen-specific apoptosis of human T cells.  |  Gribben, JG., et al. 1995. Proc Natl Acad Sci U S A. 92: 811-5. PMID: 7846057

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-CTLA-4 Antibody (F-8) has 60 citations in a variety of scientific publications.

Primary antibodies like Anti-CTLA-4 Antibody (F-8) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

CTLA-4 Antibody (F-8) Specifications

Alternate Product Name: CTLA4

Product Clone Name: F-8

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG₁ kappa light chain

Amino Acids: 195-223

Epitope Target: CTLA-4

Epitope Species: human

Product Reactivity/Detection: CTLA-4

Species Reactivity/Detection: mouse, rat, human

Additional Mammalian Reactivity: equine, canine, bovine and porcine

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, IHC(P), ELISA

Vialing Information: Each vial contains 200 µg IgG₁ kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 60 citations in various scientific publications

Available Conjugates/Forms for CTLA-4 Antibody (F-8): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, P: Blocking Peptide, PE: Phycoerythrin